MetaCap

Elicio Therapeutics (ELTX) vs Talphera (TLPH)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Talphera (TLPH) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 41.4% versus a loss of 82.8%. Over five years, TLPH leads with a -94.0% price change compared with -96.1% for ELTX. Elicio Therapeutics is the larger company by market cap ($41.0 million vs $40.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ELTX-82.84%TLPH-41.40%
+84%-4%-91%
Nov 21, 20251 yearNov 20, 2026
ELTX-96.46%TLPH-94.55%
+5%-49%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ELTX versus TLPH key metrics
MetricELTXTLPH
Share price$1.45$0.7852
Market cap$41.05M$40.80M
1-day change-3.33%+6.25%
YTD return-81.78%-31.12%
1-year return-82.84%-41.40%
5-year return-96.13%-93.96%
EPS (TTM)$-1.81$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$28.00K
Net income (latest FY)$-39.57M$-14.29M
Operating margin—-48157.14%
Net margin—-51035.71%
52-week high$16.00$1.57
52-week low$1.25$0.69
Distance from 52-week high-90.94%-49.99%
Analyst consensusstrong_buynone
Avg. price target upside+842.76%+298.62%
Average volume324.71K144.13K
Shares outstanding28.31M51.96M
Employees3312
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TLPH has outperformed ELTX by 41.4 percentage points over the past year.

About Elicio Therapeutics

ELTX stock →

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.

Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees

About Talphera

TLPH stock →

Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ELTX vs TLPH FAQ

Which is bigger, Elicio Therapeutics or Talphera?

Elicio Therapeutics (ELTX) is larger, with a market capitalization of $41.05M compared with $40.80M for Talphera (TLPH).

Which stock has performed better over the past year, ELTX or TLPH?

TLPH returned -41.40% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.

Are Elicio Therapeutics and Talphera in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons